Treatment Protocols: An Overview for Clinicians
This page offers a high-level orientation to how light-based treatment is structured in practice. It is deliberately non-prescriptive: specific parameters, session counts and sequencing are defined by the device Instructions for Use and the clinician's judgement for the individual patient. The aim here is to convey the shape of treatment, not to substitute for the IFU.
Diagnose, classify, then treat
Treatment follows from a proper workup. The TFOS DEWS III pathway, screen with OSDI-6, confirm with a single sign, and assess staining, also generates the driver profile that steers therapy (TFOS DEWS III, 2025, American Journal of Ophthalmology). The principle is to match each identified driver to a treatment with a genuine evidence base, ideally choosing an intervention that addresses several drivers at once.
The role of each modality
LM™ LLLT (PBM) serves as the primary modality, because it acts across the tear film, eyelids and ocular surface and has a favourable tolerability profile. OPE™ IPL is added as an adjunct for severe or recalcitrant meibomian gland dysfunction with a meaningful inflammatory and vascular component at the lid. The eye-light® platform delivers both, allowing the clinician to sequence them within one workflow.
Codified, delegable delivery
The platform is plug-and-play and its protocols are codified, so once the clinician has set the plan, delivery can be delegated to a trained technician. This keeps the training load on a practice low and frees clinical time, while the diagnosis, plan and monitoring remain the clinician's responsibility.
Course and review
Light-based therapy is typically delivered as a course of sessions, after which response is reviewed against baseline measures. Many patients maintain benefit between courses, and validated home therapy such as my-mask® can support maintenance where appropriate. Throughout, the device IFU governs the specifics, and treatment is used within locally cleared indications. For candidate selection, see patient selection.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.